Advertisement

Interferon as an Antitumor Agent for Urologic Tumors

  • Timothy L. Ratliff
  • Amos Shapiro
  • William J. Catalona
  • Mathilde Krim
Part of the Cancer Treatment and Research book series (CTAR, volume 19)

Abstract

In recent years there has been considerable interest in interferon (IFN) as a possible antitumor agent. Numerous clinical trials have been performed on tumors of diverse origins but a clear definition of the usefulness of IFN as an antitumor agent remains elusive.

Keywords

Renal Cell Carcinoma Antitumor Agent Interferon Treatment Biological Response Modifier Human Interferon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adam C, Thona Y, Ronco P, Verroust P, Tovey M, Morel-Maroger L: The effect of exogenous interferon: Acceleration of autoimmune and renal diseases in (NZB/W)F1 mice. Clin Exp Immunol 40:373, 1980.PubMedGoogle Scholar
  2. 2.
    Aguet M: High-affinity binding of 125I-labeled mouse interferon to a specific cell surface receptor. Nature 284:459, 1980.PubMedGoogle Scholar
  3. 3.
    Aguet M, Belardelli F, Blanchard B, Marcucci F, Gresser I: High-affinity binding of 125I-labeled mouse interferon to a specific cell surface receptor. IV. Mouse gamma interferon and cholera toxin do not compete for the common receptor site of alpha/beta interferon. Virology 117:541, 1982.PubMedGoogle Scholar
  4. 4.
    Aleman C, Khan A, Hill JM, Pardue A, Hilario R, Hill NO: Response of diffuse transitional cell carcinoma to low dose interferon. 18th Annual ASCO meeting (Abstract), 1982.Google Scholar
  5. 5.
    Ankel H, Krishnamurti C, Besançon F, Stefanos S, Falcoff E: Mouse fibroblast (type I) and immune (type II) interferons: Pronounced differences in affinity for gangliosides and in antiviral and antigrowth effects on mouse leukemia L-1210R cells. Proc Natl Acad Sci USA 77:2528, 1980.PubMedGoogle Scholar
  6. 6.
    Balkwill F, Moodie EM, Freedman V, Fantes KH: Human interferon inhibits the growth of established human breast tumors in the nude mouse. Int J Cancer 30:231, 1982.PubMedGoogle Scholar
  7. 7.
    Balkwill F, Taylor.Papdimitriore J, Fantes KH, Sebesteng A: Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenographs in athymic (nude) mice. Eur J Cancer 16:569, 1980.PubMedGoogle Scholar
  8. 8.
    Baron S, Merigan TC, McKerlie ML: Effect of crude and purified interferons on the growth of unifected cells in culture. Proc Soc Exp Biol Med 121:50, 1966.PubMedGoogle Scholar
  9. 9.
    Bast RC, Bast BS: Non-specific immunostimulation as therapy for cancer. Critical review of previously reported animal studies of tumor immunotherapy with non-specific immunostimulants. Ann NY Acad Sci 277:60, 1976.PubMedGoogle Scholar
  10. 10.
    Belardelli F, Gresser I, Maury C, Maunoury M-T: Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. Int J Cancer 30:813, 1982.PubMedGoogle Scholar
  11. 11.
    Belardelli F, Gresser I, Maury C, Maunoury M-T: Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms. Int J Cancer 30:821, 1982.PubMedGoogle Scholar
  12. 12.
    Berendt MJ, North RJ, Kerstein DP: The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell mediated immunity. J Exp Med 148:1550, 1978.PubMedGoogle Scholar
  13. 13.
    Berendt MJ, North RJ: T cell mediated suppression of anti-tumor immunity. J Exp Med 151:69, 1980.PubMedGoogle Scholar
  14. 14.
    Bernstein ID, Thor DE, Zbar B, Rapp HJ: Tumor immunity: tumor suppression in vivo initiated by soluble products of specifically stimulated lymphocytes. Science 172:729, 1971.PubMedGoogle Scholar
  15. 15.
    Blalock JE: A small fraction of cells communicates the maximal interferon sensitivity to a population (40622). Proc Soc Exp Biol Med 162:80, 1979.PubMedGoogle Scholar
  16. 16.
    Blalock JE, Georgiades JA, Langford MP, Johnson HM: Purified human immune interferon has more potent anticellular activity than fibroblasts or leukocyte interferon. Cell Immunol 49:390, 1980.PubMedGoogle Scholar
  17. 17.
    Bocci V: Pharmacokinetic studies of interferons. Pharmac Ther 13:421–440, 1981.Google Scholar
  18. 18.
    Borden EC, Holland JF, Dao TL, Gutterman JU, Wiener L, Chang Y-C, Patel J: Leukocyte-derived interferon (alpha) in human breast carcinoma. Ann Intern Med 97:1, 1982.PubMedGoogle Scholar
  19. 19.
    Borden EC, Hogen TF, Voelkel JG: Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res 42:4948, 1982.PubMedGoogle Scholar
  20. 20.
    Bradley EC, Ruscetti FW: Effect of fibroblast, lymphoid and myeloid interferons on human tumor colony formation in vitro. Cancer Res 41:244, 1981.PubMedGoogle Scholar
  21. 21.
    Branca AA, Baglioni C: Evidence that types I and II interferons have different receptors. Nature 294:768, 1981.PubMedGoogle Scholar
  22. 22.
    Cesario T, Tilles JG: Inactivation of human interferon by urine. J Infect Dis 127:311, 1973.PubMedGoogle Scholar
  23. 23.
    Christophersen IS, Jordal R, Osther K, Lindenberg J, Pedersen PH, Berg K: Interferon therapy in neoplastic disease. Acta Med Scand 204:471, 1978.PubMedGoogle Scholar
  24. 24.
    Czarniecki CW, Fennie CW: Potentiation of cell growth inhibitory effects with combinations of human recombinant α, β and γ interferons. Third Annual International Congress for Interferon Research (Abstract), 1982.Google Scholar
  25. 25.
    DeClercq E, Georgiades J, Edy VG, Sobis S: Effect of human and mouse interferon and of polyriboinosinic acid: polyribocytidylic acid on the growth of human fibrosarcoma and melanoma tumors in nude mice. Eur J Cancer 14:1273, 1978.Google Scholar
  26. 26.
    DeClercq E, Zhang Z-X, Huygen K: Synergism in the antitumor effects of type I and type II interferon in mice inoculated with leukemia L1210 cells. Cancer Lett 15:223, 1982.Google Scholar
  27. 27.
    Deryneck R, Leung DW, Gray PW, Goeddel DV: Human interferon γ is incoded by a single class of mRNA. Nucl Acids Res 10:3605, 1982.Google Scholar
  28. 28.
    Dukes PP, Izadi P, Ortega JA, Shore NA, Gomperts E: Inhibitory effects of interferon on mouse megakaryocytic progenitor cells in culture. Exp Hematol 8:1048, 1980.PubMedGoogle Scholar
  29. 29.
    Edy VG, Billiau A, DeSomer P: Comparisons of the rate of clearance of human fibroblast and leukocyte interferon from the circulatory system of rabbits. J Infect Dis 133:A18–A21, 1976.PubMedGoogle Scholar
  30. 30.
    Edy VG, Billiau A, DeSomer P: Non-appearance of injected fibroblast interferon in circulation. Lancet 1:451, 1978.PubMedGoogle Scholar
  31. 31.
    Epstein LB, Marcus SG: Review of experience with interferon and rug sensitivity testing of ovarian carcinoma in semisolid agar culture. Cancer Chemother Pharmacol 6:273, 1981.PubMedGoogle Scholar
  32. 32.
    Evinger M, Rubinstein M, Pestka S: Antiproliferative and antiviral activities of human leukocyte interferons. Arch Biochem Biophys 210:319, 1981.PubMedGoogle Scholar
  33. 33.
    Evinger M, Maeda S, Pestka S: Recombinant human leukocyte interferon produced in bacteria has antiproliferative activity. J Biol Chem 256:2113, 1981.PubMedGoogle Scholar
  34. 34.
    Farrar WL, Johnson HM, Farrar JJ: Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J Immunol 126:1120, 1980.Google Scholar
  35. 35.
    Fidler I: Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. J Science 208:1469, 1980.Google Scholar
  36. 36.
    Fidler IJ, Sone S, Fogler WE, Barnes ZL: Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78:1680, 1981.PubMedGoogle Scholar
  37. 37.
    Fleischman WR, Kleyn KM, Baron S: Potentiation of antitumor effect of virus-induced interferon by mouse immune interferon preparations. J Natl Cancer Inst 65:963, 1980.Google Scholar
  38. 38.
    Glasgow AH, Nimberg RB, Menzoian JO, Saporoschetz I, Cooperband SR, Schmidt K, Mannick JA: Association of energy with an immunosuppressive peptide fraction in the serum of patiens with cancer. N Engl Med 291:1263, 1974.Google Scholar
  39. 39.
    Glasgow LA: Leukocytes and interferon in the host response to viral infections. II. Enhanced interferon response of leukocytes from immune animals. J Bacteriol 91:2185, 1966.PubMedGoogle Scholar
  40. 40.
    Golub SH, Dorey F, Hara D, Morton DL, Burk MW: Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell populations. J Natl Cancer Inst 68:703, 1982.PubMedGoogle Scholar
  41. 41.
    Grant S, Bhalla K, Weinstein JB, Pestka S, Fisher PB: Differential effect of recombinant human leukocyte interferon on leukemic and normal myeloid progenitor cells. Biochem Biophys Res Commun 108:1048, 1982.PubMedGoogle Scholar
  42. 42.
    Gresser I, Bourali C: Inhibition by interferon preparations of a solid malignant tumor and pulmonary metastasis in mice. Nature (New Biol) 236:78, 1972.Google Scholar
  43. 43.
    Gresser I, Bourali C: Antitumor effects of interferon in mice. J Natl Cancer Inst 45:365, 1970.PubMedGoogle Scholar
  44. 44.
    Gresser I, Tovey MG: Antitumor effects of interferon. Biochim Biophys Acta 516:231, 1978.PubMedGoogle Scholar
  45. 45.
    Gresser I, Bourali C, Levy JP: Increased survival of mice inoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci USA 63:51–57, 1969.PubMedGoogle Scholar
  46. 46.
    Gresser I, Maury C, Brouty-Boye D: On the mechanism of the antitumor effect of interferon in mice. Nature 239:167, 1972.PubMedGoogle Scholar
  47. 47.
    Gresser I, Maury C, Tovey M, Morel-Maroger L, Pontillion F: Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 263:420, 1976.PubMedGoogle Scholar
  48. 48.
    Gresser I, Guy-Grand D, Maury C, Maunoury M-T: Interferon induced peripheral lymphadenopathy in mice. J Immunol 127:1569, 1981.PubMedGoogle Scholar
  49. 49.
    Gresser I, Bandu M-T, Brouty-Boye D: Interferon and cell division. IX. Interferon-resistant L1210 cells: Characteristics and origin. J Natl Cancer Inst 52:553, 1974.PubMedGoogle Scholar
  50. 50.
    Gresser I, DeMaeyer-Guignard J, Tovey MG, DeMaeyer E: Electrophoretically pure mouse interferon exerts multiple biological effects. Proc Natl Acad Sci USA 76:5308, 1979.PubMedGoogle Scholar
  51. 51.
    Gresser I, Aguet M, Morel-Maroger L, Woodrow D, Puvion-Dutilleul F, Grillon JC, Maury C: Electrophorectically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice. Am J Pathol 102:396, 1981.PubMedGoogle Scholar
  52. 52.
    Gresser I, Tovey MG, Maury C, Chouroulinkov I: Lethality of interferon preparations for newborn mice. Nature 258:76, 1975.PubMedGoogle Scholar
  53. 53.
    Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Aleranian R, Bernhardt L, Kramer M, Speigel H, Colburn W, Trown P, Merigan T, Diewanowski Z: Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance and biologic effects in cancer patients. Ann Intern Med 96:549, 1982.PubMedGoogle Scholar
  54. 54.
    Gutterman JU, Rios A, Quesada JR, Rosenblum M: Partially pure human immune (gamma) interferon: A phase I pharmacological study in cancer patients. Abstract Third Annual Congress for Interferon Research, 1982.Google Scholar
  55. 55.
    Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Aleranian R, Bernhardt L, Kramer M, Speigel H, Colburn W, Trown P, Merigan T, Diewanowska Z: Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance and biologic effects in cancer patients. Ann Intern Med 96:549, 1982.PubMedGoogle Scholar
  56. 56.
    Hanna N, Fidler U: Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 65:801, 1980.PubMedGoogle Scholar
  57. 57.
    Hellstrom KE, Hellstrom J: Immunologic enhancement of tumor growth. In: Mechanisms of Tumor Immunity, Green J, Cohen S, McCluskey R, (eds). New York: Wiley and Sons, Inc, p 147, 1977.Google Scholar
  58. 58.
    Heremans H, Billian A, Colombatti C, Hilgers J, DeSomer P: Interferon treatment of NZB mice: Accelerated progression of autoimmune disease. Infect Immun 21:925, 1978.PubMedGoogle Scholar
  59. 59.
    Hibbs JB, Chapman HA, Weinberg JB: The macrophage as an antineoplastic surveillance cell: Biologic perspectives. J Reticuloendothelial Soc 24:549, 1978.Google Scholar
  60. 60.
    Ho M: Recent advances in the study of interferon. Pharmacol Rev 34:119, 1982.PubMedGoogle Scholar
  61. 61.
    Horoszewicz JS, Leong SS, Ito M, Buffet RF, Karakousi C, Holyoke E, Job L, Dolen JG, Carter WA: Human fibroblast interferon in human neoplasia: Clinical and laboratory study. Cancer Treatm Rep 62:1899, 1978.Google Scholar
  62. 62.
    Ikic D, Kirhmajer V, Maricic Z, Jusic D, Krusic J, Knezevic M, Rode B, Soos E: Application of human leukocyte interferon in patients with carcinoma of the uterine cervix. Lancet 1:1027, 1981.PubMedGoogle Scholar
  63. 63.
    Ikic D, Maricic Z, Oresic V, Rode B, Nola P, Smudj K, Knezevic M, Jusic D: Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer and melanoma. Lancet 1:1022, 1981.PubMedGoogle Scholar
  64. 64.
    Ikic P, Singer Z, Beck M, Soos E, Sips DJ, Jusic D: Interferon treatment of uterine cervical precancerosis. J Cancer Res Clin Oncol 101:303, 1981.PubMedGoogle Scholar
  65. 65.
    Isaacs A, Lindenmann J: Virus interference: The interferon. Proc Royal Soc B147:258, 1957.Google Scholar
  66. 66.
    Johnson HM, Stanton JG, Baron S: Relative ability of mitogens to stimulate production of interferon by lymphoid cells and to induce suppression of the in vitro immune response (39622). Proc Soc Exp Biol Med 154:138, 1977.PubMedGoogle Scholar
  67. 67.
    Kadmon D, Shapiro A, Catalona WJ, Heston WDW, Oakley D, Ratliff TL: Effect of interferon gamma on the growth of the mouse bladder tumor, MBT-2, as determined by a clonogenic assay (submitted).Google Scholar
  68. 68.
    Kasai J, Leclerc JC, McVay-Boudreau L, Shen FW, Cantor H: Direct evidence that natural killer cells in non-immune spleen cell populations prevent tumor growth in vivo. J Exp Med 149:1260, 1979.PubMedGoogle Scholar
  69. 69.
    Kassel RL, Pascan PR, Vas A: Interferon-mediated oncolysis in spontaneous murine leukemia. J Natl Cancer Inst 48:1155, 1972.PubMedGoogle Scholar
  70. 70.
    Kawase I, Urdel DL, Brooks CG, Henney CS: Selective depletion of NK cell activity in vivo and its effect on the growth of NK-sensitive and NK-resistant tumor cell variants. Int J Cancer 29:567, 1982.PubMedGoogle Scholar
  71. 71.
    Knezevic M, Rode B, Knezevic-Krivak S, Ikic D, Maricic Z, Krusic J, Padovan I, Nola P, Brodarec I, Jusic D, Soos E: Histopathologic and histoenzymatic observations in carcinomas treated with human leukocyte interferon. Int J Clin Pharm Ther Tox 20:27, 1982.Google Scholar
  72. 72.
    Krim M: Towards tumor therapy with interferons. Part I. Interferons: production and properties. Blood 55:711, 1980.PubMedGoogle Scholar
  73. 73.
    Krusic J, Kirhmajer V, Knezevic M, Skic D, Maricic Z, Rode B, Jusic D, Soos E: Influence of human leukocyte interferon on squamous cell carcinoma of uterine cervix: Clinical, histological and histochemical observations. J Cancer Res Clin Oncol 101:309, 1981.PubMedGoogle Scholar
  74. 74.
    Lambert PH, Dixon FJ: Pathogenesis of the glomerulonephritis of NZB/W mice. J Exp Med 127:507, 1968.PubMedGoogle Scholar
  75. 75.
    Leandersson T, Lundgren E: Antiproliferative effect of interferon on a Burkitt’s lymphoma cell line. Exp Cell Res 130:421, 1980.PubMedGoogle Scholar
  76. 76.
    Lee SHS, Epstein LB: Reversible inhibition by interferon of the maturation of human peripheral blood monocytes to macrophages. Cell Immunol 50:177, 1980.PubMedGoogle Scholar
  77. 77.
    Ludwig H, Swetly P: In vitro inhibitory effect of interferon on colony formation of myeloma stem cells. Cancer Immunol Immunother 9:139, 1980.Google Scholar
  78. 78.
    Lutton JD, Levere RD: Suppressive effects of human interferon on erythroid colony growth in disorders of erythropoiesis. J Lab Clin Med 96:328, 1980.PubMedGoogle Scholar
  79. 79.
    Madajewicz S, Creaven P, Ozer H, O’Malley J, Grossmayer B, Pontes E, Mittelman A, Soloman J, Ferraresi R: A phase I study of rising doses of recombinant DNAα2 interferon from E. coli. Abstract Third Annual International Congress on Interferon Research, 1982.Google Scholar
  80. 80.
    Maricic Z, Nola P, Skic C, Smudj K, Oresic V, Knezevic M, Rode B, Jusic D, Soos E: Human leukocyte interferon in therapy of patients with urinary bladder papillomatosis, breast cancer and melanoma. J Cancer Res Clin Oncol 101:317, 1981.PubMedGoogle Scholar
  81. 81.
    Mastrangelo MJ, Berd D, Bellet RE: Critical review of previously reported clinical trials of cancer immunotherapy with non-specific immunostimulants. Ann NY Acad Sci 277:94, 1976.PubMedGoogle Scholar
  82. 82.
    McPherson TA, Tan YH: Phase I pharmacotoxicology study of human fibroblast interferon in human cancers. J Natl Cancer Inst 65:75, 1980.PubMedGoogle Scholar
  83. 83.
    Mogensen KE, Bandu M-T, Vignaux F, Aguet M, Gresser I: Binding of 125I-labeled human α interferon to human lymphoid cells. Int J Cancer 28:575, 1981.PubMedGoogle Scholar
  84. 84.
    Morel-Maroger L: Glomerular lesions induced by interferon. Transplant Proc 14:499, 1982.PubMedGoogle Scholar
  85. 85.
    Moss J, Woodrow DF, Sloper JC, Riviere Y, Grillon JC, Gresser I: Interferon as a cause of endoplasmic reticulum abnormalities within hepatocytes in newborn mice. Br J Exp Pathol 63:43, 1982.PubMedGoogle Scholar
  86. 86.
    Murphy GP: Current report on the interferon program at Roswell Park Memorial Institute. J Surg Oncol 17:99, 1981.PubMedGoogle Scholar
  87. 87.
    Ortega JA, Ma A, Shore NA, Dukes PP, Merigan TC: Suppressive effects of interferon on erythroid cell proliferation. Exp Hematol 7:145, 1979.PubMedGoogle Scholar
  88. 88.
    Osther K, Hill NO: Personal communication.Google Scholar
  89. 89.
    Osther K, Salford LG, Hornmark-Stenstam B, Flodgren P, Christopherson IS, Magnusson et al.: In: The Biology of the Interferon System, DeMaeyer E, Galasso G, Schellekens H (eds). Amsterdam: Elsevier/North Holland Biomedical Press, pp 415–419, 1981.Google Scholar
  90. 90.
    Pacini A, Bocci V, Muscettola M, Panlesu L, Pessina GP, Russi M: In: Interferon: Properties and Clinical Uses, Khan A, Hill NO, Dorn GL (eds). Dallas, Texas: Leland Fikes Foundation Press, pp 291–298, 1979.Google Scholar
  91. 91.
    Panniers LRV, Clemens MJ: Inhibition of cell division by interferon: changes in cell cycle characteristics and in morphology of Ehrlich ascites tumour cells in culture. J Cell Sci 48:259, 1981.PubMedGoogle Scholar
  92. 92.
    Paucker K, Cantell K, Henle W: Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology 17:324, 1962.PubMedGoogle Scholar
  93. 93.
    Priestman TJ, Lucken RN, Finter NB: Toxicity of inferferon. Br Med J 283:562, 1981.Google Scholar
  94. 94.
    Quesada JR, Swanson DA, Trindade A, Gutterman JU: Renal cell carcinoma: Antitumor effects of leukocyte interferon. Cancer Res 43:940, 1983.PubMedGoogle Scholar
  95. 95.
    Rohatiner AZS, Balkwill FR, Griffin DB, Malpas JS, Lister TA: A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmacol 9:97, 1982.PubMedGoogle Scholar
  96. 96.
    Sarkar FH: Pharmacokinetic comparison of leukocyte and Escherichia coli derived human interferon type alpha. Antiviral Res 2:103–106, 1982.PubMedGoogle Scholar
  97. 97.
    Scorticatti CH, De La Pena NC, Bellora OA, Mariotto RA, Casabe AR, Comolli R: Systemic IFN-alpha treatment of multiple bladder papilloma grade I or II patients: Pilot study. J Interferon Res 2:339, 1982.PubMedGoogle Scholar
  98. 98.
    Senik A, Stefanos S, Kolb JP, Lucero M, Falcoff E: Enhancement of mouse natural killer cell activity by type II interferon. Ann Immunol (Inst Pasteur) 131C:349, 1980.Google Scholar
  99. 99.
    Sergiescu D, Cerutti I, Kahan A, Pialier D, Efthymiou E: Isoprinosine delays the early appearance of autoimmunity in (NZB/NZW)F1 mice treated with interferon. Clin Exp Immunol 43:36, 1981.PubMedGoogle Scholar
  100. 100.
    Sergriescu D, Cerutti I, Efthymiore E, Kahan A, Chany C: Adverse effects of interferon treatment on the life span of NZB mice. Biomed 31:48, 1979.Google Scholar
  101. 101.
    Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ, Schoenberger C, Maluish AE, Oldham RK: A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. J Am Med Assoc 248:2461, 1982.Google Scholar
  102. 102.
    Smedley H, Kartrak M, Sikora K, Wheeler T: Neurological effects of recombinant human interferon. Br Med J 286:262, 1983.Google Scholar
  103. 103.
    Sonnenfeld G, Mandell AD, Merigan TC: The immunosuppressive effect of type II mouse interferon preparations on antibody production. Cell Immunol 34:193, 1977.PubMedGoogle Scholar
  104. 104.
    Stackpole C, Jacobson J: Escape from immune destruction. In: Handbook of Cancer Immunology, Waters H (ed). New York: Garland Publishing, Inc, p 55, 1978.Google Scholar
  105. 105.
    Stewart II WE: In: The Interferon System. New York, NY: Springer-Verlag, 1979.Google Scholar
  106. 106.
    Taetle R, Buick RN, McCulloch EA: Effect of interferon on colony formation in culture by blast cell progenitors in acute myeloblastic leukemia. Blood 56:549, 1980.PubMedGoogle Scholar
  107. 107.
    Taramelli D, Holden HT, Varesio L: In vitro induction of tumoricidal and suppressor macrophages by lymphokines: possible feedback regulation. J Immunol 126:2123, 1981.PubMedGoogle Scholar
  108. 108.
    Tomita Y, Cantell K, Kuwata T: Effects of human gamma interferon on cell growth, replication of virus and induction of 2′-5′-oligo-adenylate synthetase in three human lymphoblastoid cell lines and K562 cells. Int J Cancer 30:161, 1982.PubMedGoogle Scholar
  109. 109.
    Tsuruo T, Vida H, Tsukazoski S, Oku T, Kishida T: Different susceptibilities of cultures mouse cell lines to mouse interferon. Gann 73:42, 1982.PubMedGoogle Scholar
  110. 110.
    Tyring S, Klimpel GP, Fleischmann WR, Baron S: Direct cytolysis by partially-purified preparations of immune interferon. Int J Cancer 30:59, 1982.PubMedGoogle Scholar
  111. 111.
    Verma DS, Spitzer G, Gutterman JU, Beran M, Zander AR, McCredie KB: Human leukocyte interferon-mediated granulopoietic differentiation arrest and its abrogation by lithium carbonate. Am J Hematol 12:39, 1982.PubMedGoogle Scholar
  112. 112.
    Verma DS, Spitzer G, Zander AR, Gutterman JU, McCredie KB, Dicke KA, Johnston DA: Human leukocyte interferon preparation-mediated block of granulopoietic differentiation in vitro. Exp Hematol 9:63, 1981.PubMedGoogle Scholar
  113. 113.
    Von Hoff DD, Gutterman J, Portnoy B, Coltman CA Jr: Activity of human leukocyte interferon in a human tumor cloning system. Cancer Chemother Pharmacol 8:99, 1982.Google Scholar
  114. 114.
    Wallach D, Fellous M, Revel M: Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 299:833, 1982.PubMedGoogle Scholar
  115. 115.
    Warren SL: Practitioner’s guide to interferon. Ann Allergy 45:37, 1980.PubMedGoogle Scholar
  116. 116.
    Wheelock EF: Interferon-like virus inhibitor induced in human leukocytes by phytohemagglutinin. Science 169:310, 1965.Google Scholar
  117. 117.
    Zhang Z-X, DeClercq E, Heremans H, Verhaegen-Lewalle M, Content J: Antiviral and anticellular activities of human and murine type I and type II interferons in human cells monosomic, disomic and trisomic for chromosome 21. Proc Soc Exp Biol Med 170:103, 1982.PubMedGoogle Scholar

Reference

  1. 1.
    Aguet M: High-affinity binding of 125I-labeled mouse interferon to a specific cell surface receptor. Nature 284:459–461, 1980.PubMedGoogle Scholar
  2. 2.
    Aguet M, Vignaux F, Fridman WH, Gresser I: Enhancement of Fc gamma receptor expression in interferon treated mice. Eur J Immunol 11:926–930, 1981.PubMedGoogle Scholar
  3. 3.
    Aleman C, Khan A, Hill JM, Pardue A, Hilario R, Hill NO: Response of diffuse transitional cell carcinoma to low dose interferon. 18th Annual ASCO Meeting (Abstract), 1982.Google Scholar
  4. 4.
    Balkwill FR, Moodie EM, Freedman V, Fantes KH: Human interferon inhibits the growth of established human breast tumors in the nude mouse. Int J Cancer 30:231–235, 1982.PubMedGoogle Scholar
  5. 5.
    Blanchet-Bardon C, Puissant A, Lutzner M, Orth G, Nutini MT, Guesry P: Interferon treatment of skin cancer in patients with epidermodysplasia verruciformis. The Lancet 1:274, 1981.Google Scholar
  6. 6.
    Bogden AE: Characterization of animal tumors: Summary. In: Progress in clinical biological research, Vol. 37. Models for prostatic cancer, Murphy GP (ed). New York: Alan R, Liss Inc, pp 303–310, 1979.Google Scholar
  7. 7.
    Borden EC, Yamamoto N, Hogan TF, Edwards BF, Bryan GT: Interferons: Preclinical rationale for trials in human bladder carcinoma. In: Interferon. Properties, mode of action, production, clinical application, Munk K, Kirchner H (ed). Basel: Karger S, pp 42–52, 1982.Google Scholar
  8. 8.
    Brouty-Boye D: Inhibitory effects of interferon on cell multiplication. Lymphokine Rep 1:99–112, 1980.Google Scholar
  9. 9.
    Brouty-Boye D, Chang YS, Chen LB: Association of phenotypic reversion of transformed cells induced by interferon with morphological and biochemical changes in the cytoskeleton. Cancer Res 41:4174–4184, 1981.PubMedGoogle Scholar
  10. 10.
    Brouty-Boye D, Gresser I: Studies on the reversibility of the transformed and neoplastic phenotype. I. Progressive reversion of the phenotype of X-ray transformed C3H/10T1/2 cells under prolonget treatment with interferon. Int J Cancer 28:165–173, 1981.PubMedGoogle Scholar
  11. 11.
    Brouty-Boye D, Puvion-Dutilleul F, Gresser I: Reversibility of the transformed and neoplastic phenotype. III. Long-term treatment with electrophoretically pure mouse interferon leads to the progressive reversion of the phenotype of X-ray transformed C3H/10T1/2 cells. Experientia 38:1292–1296, 1982.PubMedGoogle Scholar
  12. 12.
    Bryan GT: The pathogenesis of experimental bladder cancer. Cancer Res 37:2813–2816, 1977.PubMedGoogle Scholar
  13. 13.
    Chany C, Mathieu D, Gregoire A: Induction of delta 3(4) ketosteroid synthesis by interferon in mouse adrenal tumor cell cultures. J Gen Virol 50:447–450, 1980.PubMedGoogle Scholar
  14. 14.
    Chany C, Rousset S, Bourgeade MF, Mathieu D, Gregoire A: Role of receptors and the cytoskeleton in reverse transformation and steroidogenesis induced by interferon. In: Regulatory functions of interferons, Vilcek J, Gresser I, Merigan TC (eds). Ann NY Acad Sci 350:254–265, 1980.Google Scholar
  15. 15.
    Chany C, Vignal M: Effect of prolonged interferon treatment on mouse embryonic fibroblasts transformed by murine sarcoma virus. J Gen Virol 7:203–210, 1970.PubMedGoogle Scholar
  16. 16.
    Christophersen IS, Jordal R, Osther K, Lindenberg J, Pedersen PH, Berg K: Interferon therapy in neoplastic disease. Acta Med Scand 204:471–476, 1978.PubMedGoogle Scholar
  17. 17.
    Creagan ET, Ahmann DL, Green SJ, Schutt AJ, Rubin J, Long HJ, Fein S, O’Fallon JR: Recombinant leukocyte A interferon (RO 22–8181; rIFN-αA) in disseminated malignant melanoma (DMM). ASCO Abstracts, p 58, 1983.Google Scholar
  18. 18.
    DeKernion JB, Ramning KP, Smith PB: The natural history of metastatic renal cell carcinoma: A computer analysis J Urol 120:148–152, 1978.PubMedGoogle Scholar
  19. 19.
    Djeu JY, Timonen T, Herberman RB: Augmentation of natural killer cell activity and induction of interferon by tumor cells and other biological response modifiers. In: Progress in cancer research and therapy. Mediation of cellular immunity in cancer by immune modifiers, Chrigos MA, Mitchell M, Mastrangelo MJ, Krim M, (eds). New York: Raven Press 19:161–166, 1981.Google Scholar
  20. 20.
    Dore-Duffy P, Perry W, Kuo HH: Interferon-mediated inhibition of prostaglandin synthesis in human mononuclear leukocytes. Cell Immunol 79:232–239, 1983.PubMedGoogle Scholar
  21. 21.
    Eidinger D, Morales A: BCG immunotherapy of metastatic adenocarcinoma of the kidney. Natl Cancer Inst Monogr 49:339–341, 1978.PubMedGoogle Scholar
  22. 22.
    Einhorn S, Ahre A, Blomgren H, Johansson B, Mellstedt H, Strander H: Interferon and natural killer cell activity in multiple myeloma. Lack of correlation between interferon induced enhancement of natural killer activity and clinical response to human interferon alpha. Int J Cancer 30:167–172, 1982.PubMedGoogle Scholar
  23. 23.
    Ernstoff MS, Reiss M, Davis CA, Rudnick SA, Kirkwood JM: Intravenous (i.v.) recombinant alpha-2 interferon (IFNα-2) in metastatic melanoma. ASCO Abstracts, p 57, 1983.Google Scholar
  24. 24.
    Fellous M, Kamoun M, Gresser I, Bono R: Enhanced expression of HLA antigens and beta 2-microglobulin on interferon-treated human lymphoid cells. Eur J Immunol 9:446–449, 1979.PubMedGoogle Scholar
  25. 25.
    Foon K (unpublished): Report of the National Biological Response Modifiers Program to NIH Interferon Workshop, September 28–30, 1983.Google Scholar
  26. 26.
    Frayssinet C, Gresser I, Tovey M, Lindahl P: Inhibitory effect of potent interferon preparations on the regenaration of mouse liver after partial hepatectomy. Nature 245:146–147, 1973.PubMedGoogle Scholar
  27. 27.
    Freed SZ, Halperin JP, Gordon M: Idiopathic regression of metastases from renal cell carcinoma. J Urol 118:538–542, 1977.PubMedGoogle Scholar
  28. 28.
    Fridman WH, Gresser I, Bandu M-T, Aguet M, Neauport-Santes C: Interferon enhances the expression of Fcγ receptors. J Immunol 124:2436–2441, 1980.PubMedGoogle Scholar
  29. 29.
    Glasgow LA, Crane JL Jr, Kern ER, Younger JS: Antitumor activity of interferon against murine osteogenic sarcoma in vitro and in vivo. Cancer Treat Rep 62:1881–1888, 1978.PubMedGoogle Scholar
  30. 30.
    Golub SH, D’Amore P, Rainey P: Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity. J Natl Cancer Inst 68:711–717, 1982.PubMedGoogle Scholar
  31. 31.
    Gresser I: Antitumor effects of interferon. In: Cancer — A comprehensive treatise, Vol 5, Chemotherapy, Becker F (ed). New York: Plenum Press, pp 521–571, 1977.Google Scholar
  32. 32.
    Gresser I: How does interferon inhibit tumor growth? Phil Trans Roy Soc London B299:69–76, 1982.Google Scholar
  33. 33.
    Gresser I, Bandu M-T, Brouty-Boye D: Interferon and cell division. IX. Interferon-resistant L1210 cells: Characteristics and origin. J Natl Cancer Inst 52:553.559, 1974.PubMedGoogle Scholar
  34. 34.
    Gresser I, DeMaeyer-Guignard J, Tovey M, DeMaeyer E: Electrophoretically pure mouse interferon exerts multiple biological effects. Proc Natl Acad Sci USA 76:5308–5312, 1979.PubMedGoogle Scholar
  35. 35.
    Gresser I, Maury C, Brouty-Boye D: On the mechanism of the antitumor effect of interferon in mice. Nature 239:167–168, 1972.PubMedGoogle Scholar
  36. 36.
    Gresser I, Maury C, Tovey M: Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in AKR mice. Int J Cancer 17:647–653, 1976.PubMedGoogle Scholar
  37. 37.
    Gutterman JU (unpublished): Hairy cell leukemia. Report to NIH Interferon Workshop, September 28–30, 1983.Google Scholar
  38. 38.
    Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Speigel H, Colburn W, Trown P, Merigan T, Djewanowska Z: Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance and biologic effects in cancer patients. Ann Intern Med 96:549, 1982.PubMedGoogle Scholar
  39. 39.
    Haglund S, Lundquist PG, Cantell K, Strander H: Interferon therapy in juvenile laryngeal papillomatosis. Arch Oto Laryngol 107:327–332, 1981.Google Scholar
  40. 40.
    Herberman RB, Ortaldo JR, Riccardi C, Timonen T, Schmidt A, Maluish A, Djeu J: Interferon and NK cells. In: Interferons. UCLA Symposia on Molecular and Cellular Biology, Merigan TC, Friedman RM (eds). New York: Academic Press, pp 287–294, 1982.Google Scholar
  41. 41.
    Heron I, Hokland M, Berg K: Enhanced expression of β2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA 75:6215–6219, 1978.PubMedGoogle Scholar
  42. 42.
    Hersch EM, Wallace S, Johnson DE, Bracken RB: Immunological studies in human urological cancer. In: Cancer of the genitourinary tract, Johnson DE, Samuels ML, (eds). New York: Raven Press, pp 47–56, 1979.Google Scholar
  43. 43.
    Hewitt CB: Renal cell carcinoma: A clinical challenge. In: Renal Neoplasia, Stanton King J Jr, (ed). Boston: Little Brown and Company, pp 3–12, 1967.Google Scholar
  44. 44.
    Hewitt HB: Animal tumor models and their relevance to human tumor immunology. J Biol Resp Mod 1:107–119, 1982.Google Scholar
  45. 45.
    Hicks NJ, Morris AG, Burke DC: Partial reversion of the transformed phenotype of murine sarcoma virus-transformed cells in the presence of interferon: A possible mechanism for the anti-tumor effect of interferon. J Cell Sci 49:225–236, 1981.PubMedGoogle Scholar
  46. 46.
    Hill NO, Pardue A, Khan A, Aleman C, Dorn G, Hill JM: Phase I human leukocyte interferon trials in cancer and leukemia. J Clin Hematol Oncol 11:23–35, 1981.Google Scholar
  47. 47.
    Horning S (unpublished): Lymphomas. Report to NIH Interferon Workshop, September 28–30, 1983.Google Scholar
  48. 48.
    Horoszewicz J, Leong SS, Ito M, Buffet RF, Karakousi SC, Holyoke E, Job L, Dolen JG, Carter WA: Human fibroblast interferon in human neoplasia. Cancer Treatm Rep 62:1899–1906, 1978.Google Scholar
  49. 49.
    Ida S, Hooks JJ, Siraganian RP, Notkins AL: Enhancement of IgE-mediated histamine release from human basophils by viruses: Role of interferon. J Exp Med 145:892–906, 1977.PubMedGoogle Scholar
  50. 50.
    Ikic D, Maricic Z, Oresic V, Rode B, Nola P, Smudj K, Knezevic M, Jusic D: Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer and melanoma. Lancet 1:1022–1024, 1981.PubMedGoogle Scholar
  51. 51.
    Kemeny N, Yagoda A, Wang Y, Field K, Wrobleski H, Whitmore W: Randomized trial of standard therapy with or without Poly I:C in patients with superficial bladder cancer. Cancer 48:2154–2157, 1981.PubMedGoogle Scholar
  52. 52.
    Kingsworth AN, McCann PP, Diekema KA, Ross JS, Malt RA: Effects of α-difluoromethylornithine on the growth of experimental Wilms’ tumor and renal adenocarcinoma. Cancer Res 43:4031–4034, 1983.Google Scholar
  53. 53.
    Kingsworth AN, Russell WE, McCann PP, Diekema KA, Malt RA: Effects of α-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line. Cancer Res 43:4035–4038, 1983.Google Scholar
  54. 54.
    Knigth E: Interferon: Effect on the saturation density to which mouse cells will grow in vitro. J Cell Biol 56:846–849, 1973.Google Scholar
  55. 55.
    Koren HS, Brandt CP, Tso CY, Laszlo J: Modulation of natural killing activity by lymphoblastoid interferon in cancer patients. J Biol Resp Modif 2:151–165, 1983.Google Scholar
  56. 56.
    Krown SE, Burk M, Kirkwood JM, Kerr D, Nordlund JJ, Morton DL, Oettgen HF: Human leukocyte interferon (HuLeIF) in malignant melanoma (MM): Preliminary report of the American Cancer Society clinical trials. Proc Am Assoc Cancer Res 22:158, 1981.Google Scholar
  57. 57.
    Krown SE, Einzig AI, Abramson JD, Oettgen HF: Treatment of advanced renal cell cancer (RCC) with recombinant leukocyte A interferon (rINF-αA). ASCO Abstracts, p 58, 1983.Google Scholar
  58. 58.
    Lindahl P, Leary P, Gresser I: Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 69:721–725, 1972.PubMedGoogle Scholar
  59. 59.
    Lindahl-Magnusson P, Leary P, Gresser I: Interferon and cell division. VI. Inhibitory effect of interferon on the multiplication of mouse embryo and mouse kidney cells in primary cultures. Proc Soc Exp Biol Med 138:1044–1050, 1971.PubMedGoogle Scholar
  60. 60.
    Louie AC, Gallaguer JG, Sikora K, Levy R, Rosenberg SA, Merigan TC: Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. Blood 58:712–717, 1981.PubMedGoogle Scholar
  61. 61.
    Madajewicz S, Creavan P, Ozer H, O’Malley J, Grossmeyer E, Pontes E, Mittelman J, Soloman J, Ferraresi R: A phase I study of rising doses of recombinant DNA α2 interferon from E.coli. Abstract Third Annual International Congress on Interferon Research, Miami, November 8–10, 1982.Google Scholar
  62. 62.
    Maluish A, Ortaldo JR, Conlon JC, Sherwin SA, Leavitt R, Strong DM, Weirnik P, Oldham RK, Herberman RB: Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon. J Immunol 131:503–507, 1983.PubMedGoogle Scholar
  63. 63.
    McDonald MW: Current therapy for renal cell carcinoma. J Urol 127:211–217, 1982.PubMedGoogle Scholar
  64. 64.
    Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Veveri JP: Catalytic irreversible inhibition of mammalian ornithine decarboxylase by substrate and product analogs. J Am Chem Soc 100:2551–2552, 1978.Google Scholar
  65. 65.
    Murphy GP, Hrushesky WL: A murine renal cell carcinoma. J Natl Cancer Inst 50:1013–1021, 1973.PubMedGoogle Scholar
  66. 66.
    Murphy GP, Williams GP: Testing of chemotherapeutic agents in murine renal cell adenocarcinoma. Res Commun Chem Pathol Pharmacol 9:265–277, 1974.PubMedGoogle Scholar
  67. 67.
    Osther K, Salford LG, Hornmark-Stenstam B, Flodgren P, Christopherson I, Magnusson K and the Southern Sweden Neuro-Oncology Group: Local versus systemic human leukocyte interferon treatment. In: The Biology of the Interferon System, DeMaeyer E, Galasso G, Schellekens H (eds). Amsterdam: Elsevier/North Holland Biomedical Press, pp 415–419, 1981.Google Scholar
  68. 68.
    Pazin GJ, Ho M, Haverkos HW, Armstrong JA, Breinig MC, Wechsler HL, Arvin A, Merigan T, Cantell K: Effects of interferon-alpha on human warts. J Interferon Res 2:235–243, 1982.PubMedGoogle Scholar
  69. 69.
    Pegg AE, McCann PP: Polyamine metabolism and function: A brief review. Am J Physiol 243:C212–C221, 1982.PubMedGoogle Scholar
  70. 70.
    Pinsky C, Camacho D, Kerr H, Herr N, Geller N, Whitmore W, Oettgen H: Treatment of superficial bladder cancer with intravesical BCG. ASCO Abstracts, #C-223, p 57, 1983.Google Scholar
  71. 71.
    Quesada JR, Ruben J, Manning JT, Hersh E, Gutterman JU: Alpha Interferon for induction of remission in hairy cell leukemia. N Eng J Med 310:15–18, 1984.Google Scholar
  72. 72.
    Quesada JR, Swanson DA, Trindade A, Gutterman JU: Renal cell carcinoma: Antitumor effects of leukocyte interferon. Cancer Res 43:940–947, 1983.PubMedGoogle Scholar
  73. 73.
    Reid LM, Minato N, Gresser I, Holland J, Kadish A, Bloom BR: Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice. Proc Natl Acad Sci USA 78:1171–1176, 1981.PubMedGoogle Scholar
  74. 74.
    Rigby CC, Franks LM: A human tissue culture cell line from a transitional cell tumor of the urinary bladder. Growth, chromosome pattern, and ultrastructure. Br J Cancer 24:746–754, 1970.PubMedGoogle Scholar
  75. 75.
    Saksela E, Timonen T, Cantell K: Human natural killer cell activity is augmented by interferon via recruitment of ‘Pre-NK’ cells. Scand J Immunol 10:257–266, 1979.PubMedGoogle Scholar
  76. 76.
    Salmon SE, Duric BGM, Young L, Lin RM, Trown PW, Stebbing N: Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 3:217–224, 1983.Google Scholar
  77. 77.
    Schellekens H, Weimar W, Cantell K, Stitz L: Antiviral effect of interferon in vivo may be mediated by the host. Nature 278:742, 1979.PubMedGoogle Scholar
  78. 78.
    Schroder EW, Chou IN, Jaken S, Black P: Interferon inhibits the release of plasminogen activator from SV 3T3 cells. Nature 276:828–829, 1978.PubMedGoogle Scholar
  79. 79.
    Schultz RM: Macrophage activation by interferon. In: Lymphokine Reports, Pick E (ed). New York: Academic Press, 1:63–97, 1980.Google Scholar
  80. 80.
    Schultz RM, Chirigos MA: Similarities among factors that render macrophages tumoricidal in lymphokine and interferon preparations. Cancer Res 38:1003–1007, 1978.PubMedGoogle Scholar
  81. 81.
    Scorticatti CH, De La Pena NC, Bellora OA, Mariotto RA, Casabe AR, Comolli R: Systemic IFN-alpha treatment of multiple bladder papilloma grade I or II patients: Pilot study. J Interferon Res 2:339–343, 1982.PubMedGoogle Scholar
  82. 82.
    Sen GC: Mechanism of interferon action: Progress towards its understanding. In: Prog Nucl Acid Res and Mol Biol, Cohn W (ed). New York: Academic Press 27:105–156, 1982.Google Scholar
  83. 83.
    Shapiro A, Kadmon D, Catalona WJ, Ratliff TL: Immunotherapy of superficial bladder cancer. J Urol 128:891–894, 1983.Google Scholar
  84. 84.
    Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ, Schoenberger C, Maluish AE, Oldham RK: A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. J Am Med Assoc 248:2461, 1982.Google Scholar
  85. 85.
    Siimes M, Seppanen P, Alhonen-Hongisto L, Janne J: Synergistic action of two polyamine antimetabolites leads to a rapid therapeutic response in childhood leukemia. Int J Cancer 28:567–570, 1981.PubMedGoogle Scholar
  86. 86.
    Skinner DG: Current perspectives in the management of high-grade invasive bladder cancer. Cancer 45:1866–1874, 1980.PubMedGoogle Scholar
  87. 87.
    Smalley RV, Oldham RK: Interferon as a biological response modifying agent in clinical trials. J Biol Resp Mod 2:401–408, 1983.Google Scholar
  88. 88.
    Smith JA, Herr HW: Spontaneous regression of pulmonary metastases from transitional cell carcinoma. Cancer 46:1499–1515, 1980.PubMedGoogle Scholar
  89. 89.
    Soloway MS: Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 37:2918–2929, 1977.PubMedGoogle Scholar
  90. 90.
    Soloway MS: CIS-diaminedichloroplatinum II in advanced urothelial cancer. J Urol 120:716, 1978.PubMedGoogle Scholar
  91. 91.
    Strander H: Interferons: Antineoplastic drugs? Blut 35:277–288, 1977.PubMedGoogle Scholar
  92. 92.
    Strander H (unpublished): Osteosarcoma. NIH Interferon Workshop, September 28–30, 1983.Google Scholar
  93. 93.
    Streevalsan T, Taylor-Papadimitriou J, Rozengurt E: Selective inhibition by interferon of serum-stimulated biochemical events in 3T3 cells. Biochem Biophys Res Commun 87:679–685, 1979.Google Scholar
  94. 94.
    Sunkara P, Prakash NJ, Mayer GD, Sjoerdsma A: Tumor suppression with a combination of α-difluoromethylornithine and interferon. Science 219:851–853, 1983.PubMedGoogle Scholar
  95. 95.
    Talpaz M, McCredie KB, Keating MJ, Gutterman JU: Clinical investigation of leukocyte interferon (HuIFN-α) in chronic myelogenous leukemia. Am Soc Hematology Meeting Abstracts, 1983.Google Scholar
  96. 96.
    Talpaz M, McCredie KB, Mavligit G, Gutterman JU: Leukocyte interferon: Control of myeloid proliferation in chronic myelogenous leukemia. Blood 62:689–692 1983.PubMedGoogle Scholar
  97. 97.
    Tamm I, Wang E, Landsberger FR, Pfeffer L: Interferon modulates cell structure and function. In: UCLA Symposia on Molecular and Cellular Biology. Interferons, Merigan TC, Friedman RM (eds). New York: Academic Press 25:159–179, 1982.Google Scholar
  98. 98.
    Targan S, Dorey F: Interferon activation of ‘pre-spontaneous killer’ (pre-SK) cells and alteration of kinetics of lysis of both ‘pre-SK’ and active SK cells. J Immunol 124:2157–2161, 1980.PubMedGoogle Scholar
  99. 99.
    Territo M, Sarna G, Figlin R: Effect of in vivo administration of interferon on human monocyte function. J Biol Resp Mod 2:450–457, 1983.Google Scholar
  100. 100.
    Todd RF III, Garnick MB, Canellos GY, Richie JP, Gittes RF, Mayer RJ, Skarin AT: Phase I-II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma. Cancer Treatm Rep 65:17, 1981.Google Scholar
  101. 101.
    Tovey MG, Brouty-Boye D: The use of the chemostat to study the relationship between cell growth rate, viability and the effect of interferon on L1210 cells. Exp Cell Res 118:383–388, 1979.PubMedGoogle Scholar
  102. 102.
    Trinchieri G, Granato D, Perussia B: Interferon-induced resistance of fibroblastst to cytolysis mediated by natural killer cells. Specificity and mechanism. J Immunol 126:335–340, 1981.PubMedGoogle Scholar
  103. 103.
    Trinchieri G, Santoli D, Dee RR, Knowles BB: Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Identification of the antiviral activity as interferon and characterization of the human effector lymphocyte subpopulation. J Exp Med 147:1299–1313, 1978.PubMedGoogle Scholar
  104. 104.
    Turek LP, Byrne JC, Lowy DR, Dvoretsky I, Friedman RM, Howley PM: Interferon induces morphologic reversion with elimination of extra-chromosomal viral genomes in bovine papillomavirus-transformed mouse cells. Proc Natl Acad Sci USA 79:7914–7918, 1982.PubMedGoogle Scholar
  105. 105.
    Uyeno K, Ohtsu A: Interferon treatment of viral warts and some skin diseases. In: Proc Conf on Clinical Potentials of Interferons in Viral Diseases and Malignant Tumors, Tokyo, Japan, December 2–4, 1980, (Abstracts, pp 32–33), 1980.Google Scholar
  106. 106.
    Vanky F, Argov SA, Einhorn S, Klein E: Role of alloantigens in natural killing. J Exp Med 151:1151–1165, 1980.PubMedGoogle Scholar
  107. 107.
    Von Hoff DD, Gutterman J, Portnoy B, Coltman CA Jr: Activity of human leukocyte interferon in a human tumor cloning system. Cancer Chemother Pharmacol 8:99–103, 1982.Google Scholar
  108. 108.
    Vose BV, Vanky E, Argou S, Klein E: Natural cytotoxicity in man: Activity of lymph node and tumor infiltrating lymphocytes. Eur J Immunol 7:753, 1977.Google Scholar
  109. 109.
    Webber MM: In vitro models for prostatic cancer: Summary. In: Progress in Clinical Biological Research, Vol. 37. Models for Prostatic Cancer, Murphy GP (ed). New York: Alan R, Liss Inc, pp 133–147, 1979.Google Scholar
  110. 110.
    Weldon TE, Soloway MS: Susceptibility of urothelium to neoplastic cellular implantation. Urology 5:824–827, 1975.PubMedGoogle Scholar
  111. 111.
    Yaron M, Yaron I, Gurari-Rotman D, Revel M, Lindner HR, Zor V: Stimulation of prostaglandin E producing cultured fibroblasts by poly(I) poly(C) and human interferon. Nature 267:457, 1977.PubMedGoogle Scholar
  112. 112.
    Young CW: Interferon induction in cancer. Med Clin North Am 55:721–728, 1971.PubMedGoogle Scholar
  113. 113.
    Zeffren J, Yagoda A, Watson RC, Natale RB, Blumenreich MS, Chapman R, Howard J: Phase II trial of methyl-GAG in advanced renal cancer. Cancer Treatm Rep 65:525, 1981.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • Timothy L. Ratliff
  • Amos Shapiro
  • William J. Catalona
  • Mathilde Krim

There are no affiliations available

Personalised recommendations